| Name | Title | Contact Details |
|---|
Carenet Health is a leading provider of healthcare consumer engagement solutions, clinical support, health advocacy and navigation solutions, and 24/7 access to medical care. Our engagement specialists, care coordinators and registered nurses support 1 in 4 Americans (more than 86 million healthcare consumers) on behalf of 250+ of the nation`s premier health plans, providers, health systems and Fortune 500 organizations. Our mission is to drive market-leading consumer engagement outcomes through our proprietary Intelligent Engagement model. Our best-practice solutions are delivered by outstanding teams and backed by clinical capital, data and technology, operational excellence and expertise from outside of healthcare. Every day, our team members guide people to high-quality and cost-effective care, and coach them to close gaps in care and improve their health. For eight consecutive years, Inc. Magazine named Carenet as one of America`s fastest-growing private companies.
NexGen Healthcare is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Windsor House Inc is a Girard, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natura Bisse International is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.